Obsidian Therapeutics is a biotechnology company that develops cell and gene therapies for the treatment of various diseases. The company's proprietary cytoDRiVE platform enables precise control of protein expression in cells, allowing for the development of therapies with enhanced safety and efficacy. Obsidian's pipeline includes therapies for cancer, autoimmune diseases, and genetic disorders. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.